LONDON (Alliance News) - Drug development firm Redx Pharma PLC on Tuesday said it has identified a candidate for its leukaemia programme.
The RX005 compound has the potential to treat patients suffering from chronic lymphocytic leukaemia, including those who become resistant to the increasingly used treatment ibrutinib, Redx said.
Redx will now progress studies to prepare the RX005 programme for its first in-human clinical trials, expected to start in early 2018.
Shares in Redx were up 6.8% to 51.00 pence on Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
